Your session is about to expire
← Back to Search
Radiation
SBRT for Prostate Cancer
Phase 1
Recruiting
Led By Jonathan Lischalk
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to year 5 post-treatment
Awards & highlights
Study Summary
This trial tests a new prostate cancer treatment that uses radiation in two doses to safely treat localized prostate cancer.
Who is the study for?
This trial is for men over 18 with localized prostate cancer, staged TX-T2c. They must have a prostate size under 60cc, no prior malignancies within the last 5 years, and agree to use effective contraception. Excluded are those with evidence of more advanced cancer spread, large prostates over 60cc, recent prostate surgeries or treatments affecting the pelvis.Check my eligibility
What is being tested?
The study tests a two-session Stereotactic Body Radiation Therapy (SBRT) targeting a dominant lesion in the prostate using MRI guidance. It's designed to see if this focused treatment is feasible and safe for patients with early-stage prostate cancer.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects may include urinary issues, bowel discomfort due to radiation exposure near these areas, fatigue from therapy sessions and skin reactions at the site of radiation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to year 5 post-treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to year 5 post-treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Grade 2 or Higher Toxicities per CTCAE version 5.0
Secondary outcome measures
Change in Expanded Prostate Cancer Index Composite (EPIC) Quality of Life Questionnaire Score
Disease-Free Survival (DFS)
Incidence of Phoenix Definition Biomechanical Failure (BCF)
+3 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Men with low to intermediate risk prostate cancerExperimental Treatment1 Intervention
Once a patient is deemed eligible, they will be scheduled for treatment with SBRT, which should be completed within 14 days of screening. Follow up will occur 30 days post radiation and every 4 months, post- radiation for the first 2 years. After the first 2 years of follow up, visits will occur every 6 months until year 5.
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,369 Previous Clinical Trials
840,518 Total Patients Enrolled
24 Trials studying Prostate Cancer
5,190 Patients Enrolled for Prostate Cancer
Jonathan LischalkPrincipal InvestigatorNYU Langone Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.My treatment plan doesn't meet specific safety limits for radiation exposure.I have had a uro lift procedure before.My condition is considered high risk.My doctor says I need radiation therapy for my lymph nodes to prevent cancer spread.My cancer has spread beyond the original organ.I have not had any other cancers in the last 5 years.My prostate is larger than 60cc according to my MRI.My prostate cancer was confirmed through a biopsy.I have had radiation treatment to my pelvic area.I have had surgery on my prostate before.I have an active severe inflammatory or rheumatological condition.My cancer is considered low to intermediate risk.I am a man willing to use contraception during the study.My prostate is smaller than 60cc according to my MRI.My doctor will decide if I need hormone therapy for my cancer.My cancer is considered low to intermediate risk and does not require an SIB.My cancer is not highly aggressive.My radiation oncologist says I need a specific procedure for my rectal area.My cancer is between stages TX and T2c according to the 8th edition staging.My prostate cancer is localized and not spread.I had a prostate surgery (TURP) within the last 6 months.My cancer has spread to the lymph nodes in my pelvis.
Research Study Groups:
This trial has the following groups:- Group 1: Men with low to intermediate risk prostate cancer
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there a current enrollment period for this research initiative?
"It is evident from clinicaltrials.gov that this trial, which was initially posted on July 1st 2023 and last updated on May 9th 2023, has ceased recruiting participants. Fortunately for those seeking to join a medical study, there are currently 1339 other trials taking in new candidates."
Answered by AI
Has the federal government given their sanction for treating men with low to intermediate risk prostate cancer?
"Men with low to intermediate risk prostate cancer have limited data regarding safety and efficacy, therefore receiving a score of 1."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger